Patents by Inventor David I. Stirling

David I. Stirling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6429221
    Abstract: Novel imides are inhibitors of tumor necrosis factor &agr; and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 2-Phthalimido-3-(3′,4′-dimethoxyphenyl)propane.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: August 6, 2002
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 6395754
    Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF&agr; in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: May 28, 2002
    Assignee: Celgene Corporation, et al.
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Publication number: 20020045643
    Abstract: Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in reducing undesirable levels of TNF&agr; in a mammal. Typical embodiments are pharmaceutical compositions containing 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Type: Application
    Filed: February 12, 2001
    Publication date: April 18, 2002
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 6335349
    Abstract: Substituted 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines and 1-oxo-2-(2,6-dioxo-piperidin-3-yl)isoindolines reduce the levels of TNF&agr; in a mammal and are useful in treating oncogenic conditions, inflammation, and autoimmune diseases. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroiso-indoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: January 1, 2002
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 6316471
    Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF&agr; in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: November 13, 2001
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 6284780
    Abstract: Novel aryl amides are inhibitors of tumor necrosis factor &agr; and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is N-benzoyl-3-amino-3-(3′,4′-dimethoxyphenyl)propanamide.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: September 4, 2001
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 6281230
    Abstract: Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: August 28, 2001
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 6046221
    Abstract: Novel aryl amides are inhibitors of tumor necrosis factor .alpha. and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)propanamide.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: April 4, 2000
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 5955476
    Abstract: 1-Oxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines and 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines reduce the levels of inflammatory cytokines such as TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3 -yl)-isoindoline.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: September 21, 1999
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen, Hon-Wah Man
  • Patent number: 5908850
    Abstract: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: June 1, 1999
    Assignee: Celgene Corporation
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani, David I. Stirling
  • Patent number: 5874448
    Abstract: 1-Oxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines and 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindoline.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: February 23, 1999
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen, Hon-Wah Man
  • Patent number: 5801195
    Abstract: Novel aryl amides are inhibitors of tumor necrosis factor .alpha. and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)propanamide.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: September 1, 1998
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 5798368
    Abstract: Tetrasubstituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: August 25, 1998
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 5736570
    Abstract: Novel aryl amides are inhibitors of tumor necrosis factor .alpha. and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)propanamide.
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: April 7, 1998
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 5733756
    Abstract: Novel lactams and processes for the preparation of chiral compounds having utility as intermediates in the synthesis of compounds with Central Nervous System stimulant activity.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: March 31, 1998
    Assignee: Celgene Corporation
    Inventors: Andrew L. Zeitlin, David I. Stirling
  • Patent number: 5703098
    Abstract: Imide/amide ethers and alcohols are inhibitors of cytokines including tumor necrosis factor .alpha. and can be used to combat cachexia, endotoxic shock, arthritis, asthma, and retrovirus replication. A typical embodiment is 3-Phthalimido-3-(3', 4'-dimethoxyphenyl)propan-1-ol.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: December 30, 1997
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 5635517
    Abstract: 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline.
    Type: Grant
    Filed: July 24, 1996
    Date of Patent: June 3, 1997
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger S. -C. Chen
  • Patent number: 5346828
    Abstract: Mixtures of enantiomeric D,L-threo 2-amino-3-hydroxy-3-phenylpropionic acids can be stereoisomerically enriched by contacting the mixture with a D-threonine aldolase. In a typical embodiment, D- and L-threo 2-amino-3-hydroxy-3-(4-methylsulfonylphenyl)propionic acid is treated with D-threonine aldolase to produce L-threo 2-amino-3-hydroxy-3-(4-methylsulfonylphenyl)propionic acid with a high ee. The benzaldehyde and amino acid formed from the D-threo isomer can be recycled.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: September 13, 1994
    Assignee: Celgene Corporation
    Inventors: David I. Stirling, Muppala S. Raju, Andrew L. Zeitlin
  • Patent number: 5300437
    Abstract: Amines in which the amino group is on a secondary carbon atom which is chirally substituted can be enantiomerically enriched by the action of an omega-amino acid transaminase which has the property of preferentially converting one of the two chiral forms to a ketone. The process also can be used to stereoselectively synthesize one chiral form from ketones substantially to the exclusion of the other.
    Type: Grant
    Filed: October 9, 1992
    Date of Patent: April 5, 1994
    Assignee: Celgene Corporation
    Inventors: David I. Stirling, George W. Matcham, Andrew L. Zeitlin
  • Patent number: 5169780
    Abstract: Amines in which the amino group is on a secondary carbon atom which is chirally substituted can be enantiomerically enriched by the action of an omega-amino acid transaminase which has the property of preferentially converting one of the two chiral forms to a ketone. The process can be used to stereoselectively sythesize one chiral form from ketones substantially to the exclusion of the other. An aqueous solution of chiral amines after being brought into contact with an omega-amino acid transaminase and an amino acceptor is treated with a water-immiscible organic solvent, the aqueous and organic phases are separated, and the aqueous phase can be recirculated for further contact with the transaminase.
    Type: Grant
    Filed: July 9, 1990
    Date of Patent: December 8, 1992
    Assignee: Celgene Corporation
    Inventors: David I. Stirling, Andrew L. Zeitlin, George W. Matcham, James D. Rozzell, Jr.